1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Pennsylvania >
  6. Castle Creek Pharmaceuticals Acquires Fibrocell Science

M&A Deal Summary

Castle Creek Pharmaceuticals Acquires Fibrocell Science

On September 12, 2019, Castle Creek Pharmaceuticals acquired life science company Fibrocell Science

Acquisition Highlights
  • This is Castle Creek Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Castle Creek Pharmaceuticals’ 1st transaction in the United States.
  • This is Castle Creek Pharmaceuticals’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2019-09-12
Target Fibrocell Science
Sector Life Science
Buyer(s) Castle Creek Pharmaceuticals
Deal Type Add-on Acquisition

Target

Fibrocell Science

Exton, Pennsylvania, United States
Fibrocell Science, Inc. is a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases.

Search 214,744 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Castle Creek Pharmaceuticals

Parsippany, New Jersey, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Castle Creek Pharmaceuticals LLC is a privately-held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. Castle Creek Pharmaceuticals LLC with offices in Parsippany, New Jersey and Chicago, Illinois, is dedicated to developing and bringing novel therapies to those living with epidermolysis bullosa.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal